{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:04:31Z","timestamp":1787025871169,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:p>BACKGROUND: The aim of the study was to longitudinally investigate the serum levels of mesothelin, sestrin1, hyaluronan synthase 2 (HAS2), midkine, and high mobility group box 1 (HMGB1) before and after chemotherapy and at the time of relapse in malignant pleural mesothelioma (MPM) patients treated with chemotherapy and to compare the changes in biomarker levels with radiological treatment outcome. METHODS: A total of 64 MPM patients treated with chemotherapy were enrolled in the study and longitudinally followed for changes in biomarker levels in response to treatment. Biomarkers levels were measured in serum using a human ELISA kit. Relative and absolute changes in biomarker levels were compared with the best radiological overall response at each time point. RESULTS: Median survival was 20.0 \u00b1 2.4 (15.3\u201324.7) months in patients with partial and complete response, 17.0 \u00b1 1.0 (15.0\u201319.0) months in patients with stable disease, and 9.0 \u00b1 1.0 (7.0\u201311.0) months in patients with progressive disease. A significant decrease in serum levels of mesothelin, midkine, and HMGB1 was observed in patients with radiologically partial and complete responses to chemotherapy (p&lt; 0.001, p= 0.016, and p= 0.039, respectively). In these patients, mesothelin levels decreased by 15%, midkine levels by 7%, and HMGB1 levels by 15%. In addition, HMGB1 serum levels were found to significantly increase by 15% in patients with radiologically progressive responses to chemotherapy compared to pretreatment serum levels (p= 0.035). In patients with partial and complete response to chemotherapy, mesothelin levels increased by 15%, midkine by 12%, and sestrin1 by 8% when the disease recurred (p= 0.004, p= 0.004 and p= 0.044, respectively). CONCLUSION: Biomarkers may be useful in the longitudinal monitoring of response to treatment in MPM. However, the results of our study should be validated in larger groups with sufficient case numbers from multicenter institutions.<\/jats:p>","DOI":"10.3233\/cbm-220436","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T12:33:45Z","timestamp":1691152425000},"page":"111-120","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers"],"prefix":"10.1177","volume":"38","author":[{"given":"Filiz","family":"Bogar","sequence":"first","affiliation":[{"name":"Eskisehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Eskisehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guntulu","family":"Ak","sequence":"additional","affiliation":[{"name":"Eskisehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Eskisehir, Turkey"},{"name":"Eskisehir Osmangazi University, Medical Faculty, Department of Chest Disease, Eskisehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Metintas","sequence":"additional","affiliation":[{"name":"Eskisehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Eskisehir, Turkey"},{"name":"Eskisehir Osmangazi University, Medical Faculty, Department of Public Health, Eskisehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Ayhanci","sequence":"additional","affiliation":[{"name":"Eskisehir Osmangazi University, Faculty of Science, Department of Biology, Eskisehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Metintas","sequence":"additional","affiliation":[{"name":"Eskisehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Eskisehir, Turkey"},{"name":"Eskisehir Osmangazi University, Medical Faculty, Department of Chest Disease, Eskisehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-220436_ref1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.3233\/CBM-220436_ref2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/ijerph15051000","article-title":"Global Asbestos Disaster","volume":"15","author":"Furuya","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.3233\/CBM-220436_ref3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.3233\/CBM-220436_ref4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3390\/ijerph14111293","article-title":"Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program","volume":"14","author":"Metintas","year":"2017","journal-title":"Int J Environ Res Public Health"},{"key":"10.3233\/CBM-220436_ref5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3233\/CBM-220436_ref6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)","volume":"13","author":"Armato 3rd","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.3233\/CBM-220436_ref7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jtho.2018.05.003","article-title":"Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.3233\/CBM-220436_ref8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/JTO.0000000000000211","article-title":"Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions","volume":"9","author":"Armato 3rd","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.3233\/CBM-220436_ref9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejrad.2009.02.002","article-title":"Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma","volume":"74","author":"Ak","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.3233\/CBM-220436_ref10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12885-017-3209-5","article-title":"Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin","volume":"17","author":"Ak","year":"2017","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-220436_ref11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5114\/aoms\/112525","article-title":"Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma","volume":"19","author":"Akgun","year":"2021","journal-title":"Archives of Medical Science"},{"key":"10.3233\/CBM-220436_ref12","doi-asserted-by":"crossref","first-page":"e72030","DOI":"10.1371\/journal.pone.0072030","article-title":"Hyaluronan and N-ERC\/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma","volume":"8","author":"Mundt","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/CBM-220436_ref13","first-page":"4183157","article-title":"HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma","volume":"12","author":"Wang","year":"2019","journal-title":"Dis Markers"},{"key":"10.3233\/CBM-220436_ref14","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions, The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.3233\/CBM-220436_ref15","doi-asserted-by":"crossref","first-page":"e013324","DOI":"10.1136\/bmjopen-2016-013324","article-title":"Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study","volume":"6","author":"Tsim","year":"2016","journal-title":"BMJ Open"},{"key":"10.3233\/CBM-220436_ref16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"10.3233\/CBM-220436_ref17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"key":"10.3233\/CBM-220436_ref18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.37349\/etat.2020.00028","article-title":"Circulating biomarkers in malignant pleural mesothelioma","volume":"1","author":"Viscardi","year":"2020","journal-title":"Explor Target Antitumor Ther"},{"key":"10.3233\/CBM-220436_ref19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.3233\/CBM-220436_ref20","first-page":"1427","article-title":"Impact of renal failure on the tumor markers of mesothelioma, N-ERC\/mesothelin and osteopontin","volume":"31","author":"Shiomi","year":"2011","journal-title":"Anticancer Res"},{"key":"10.3233\/CBM-220436_ref21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3892\/ol.2020.12389","article-title":"Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma","volume":"21","author":"Fontana","year":"2021","journal-title":"Oncol Lett"},{"key":"10.3233\/CBM-220436_ref22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12885-018-4113-3","article-title":"A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma","volume":"18","author":"de Fonseka","year":"2018","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-220436_ref23","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.3233\/CBM-220436_ref24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1155\/2012\/430689","article-title":"Soluble mesothelin-related peptides levels in patients with malignant mesothelioma","volume":"32","author":"Franko","year":"2012","journal-title":"Dis Markers"},{"key":"10.3233\/CBM-220436_ref25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-220436_ref26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"10.3233\/CBM-220436_ref27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/1471-2407-14-674","article-title":"A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice","volume":"14","author":"Linch","year":"2014","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-220436_ref28","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.3233\/CBM-220436_ref29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2021.01.011","article-title":"Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial","volume":"154","author":"Katz","year":"2021","journal-title":"Lung Cancer"},{"key":"10.3233\/CBM-220436_ref30","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma","volume":"28","author":"Wheatley-Price","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3233\/CBM-220436_ref31","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.3233\/CBM-220436_ref32","doi-asserted-by":"crossref","first-page":"5756102","DOI":"10.1155\/2017\/5756102","article-title":"Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases","volume":"2017","author":"Ying","year":"2017","journal-title":"Dis Markers"},{"key":"10.3233\/CBM-220436_ref33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-220436_ref34","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-220436_ref35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/his.13470","article-title":"Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma","volume":"72","author":"Rrapaj","year":"2018","journal-title":"Histopathology"},{"key":"10.3233\/CBM-220436_ref36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/1097-0142(19890701)64:1<68::AID-CNCR2820640112>3.0.CO;2-I","article-title":"A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease","volume":"64","author":"Dahl","year":"1989","journal-title":"Cancer"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-220436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:10:15Z","timestamp":1777385415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-220436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":36,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/cbm-220436","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}